Jennifer A Woyach
Ohio State University Comprehensive Cancer Center · Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jennifer A Woyach as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:01 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07685717 · Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic LeukemiaJennifer Woyach · recruiting · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT07557056 · Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaJennifer Woyach · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT05873712 · Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's SyndromeAseel Alsouqi · recruiting · Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma · principal investigator
- Ph1NCT04439006 · Ibrutinib for the Treatment of COVID-19 in Patients Requiring HospitalizationJennifer Woyach · completed · Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm · principal investigator
- Ph3NCT03737981 · Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI) · active not recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph3NCT01886872 · Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI) · active not recruiting · Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- OSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · fiscal years 2026 · $1,100,102 awarded in 2026Same name and institution; not confirmed by an ID
- Project 03: Leukemia and Hematological Malignancies Research (LHM)P30CA016058 · NCI · OHIO STATE UNIVERSITY · fiscal years 2024 to 2026 · $58,203 awarded in 2026Same name and institution; not confirmed by an ID
- Targeted Therapies for Lymphoid MalignanciesR01CA177292 · NCI · OHIO STATE UNIVERSITY · fiscal years 2017 to 2025 · $538,241 awarded in 2025Same name and institution; not confirmed by an ID
- Dual targeting of XPO1 and BTK in B cell malignanciesR01CA192928 · NCI · OHIO STATE UNIVERSITY · fiscal years 2015 to 2019 · $496,655 awarded in 2019Same name and institution; not confirmed by an ID
- Improving BTK Directed Therapy for CLLR01CA197870 · NCI · OHIO STATE UNIVERSITY · fiscal years 2015 to 2019 · $341,706 awarded in 2019Same name and institution; not confirmed by an ID
- Molecular Evaluation of Targeted Therapies in Lymphoid MalignanciesR01CA183444 · NCI · OHIO STATE UNIVERSITY · fiscal years 2014 to 2018 · $501,285 awarded in 2018Grant number is on one of their registry trials
- Targeted Therapies and Mechanisms of Resistance in Chronic Lymphocytic LeukemiaK23CA178183 · NCI · OHIO STATE UNIVERSITY · fiscal years 2013 to 2017 · $173,232 awarded in 2017Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT03737981, NCT01886872
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT01886872
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:01 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.N Engl J Med · 2018789 citationsRCR 27.0
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.Blood · 2013704 citationsRCR 17.9
- 563 citationsRCR 23.2
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.J Clin Oncol · 2017435 citationsRCR 12.6
- Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.Am J Hematol · 2019421 citationsRCR 16.4
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.Blood · 2016412 citationsRCR 11.5
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.Lancet · 2021399 citationsRCR 21.4
- Ibrutinib treatment improves T cell number and function in CLL patients.J Clin Invest · 2017344 citationsRCR 9.7
- 224 citationsRCR 8.4
- 213 citationsRCR 20.0